business

Enliven Therapeutics (ELVN) Soars on Stellar Leukemia Drug Trial

Yahoo Finance · Jun 13, 2026, 7:02 AM · Also reported by 3 other sources

Read full story on Yahoo Finance → More top stories

Also covered by

Investing.com Enliven Therapeutics prices $400M public offering at $37.50 Investing.com Incyte reports positive Phase 3 trial results for lymphoma drug Investing.com Piper Sandler raises Tenax Therapeutics price target on trial data

Aggregated and edited by the Scoop newsroom. We surface news from Yahoo Finance alongside other reporting so you can compare coverage in one place. Editorial policy · Corrections · About Scoop

Enliven Therapeutics (ELVN) Soars on Stellar Leukemia Drug Trial

Also covered by

More in business